验证ACLF分级与MELD评分交互作用的新评分预测等待名单死亡率
该研究基于UNOS数据库(2002年1月至2018年6月)分析18,416例成人肝硬化伴ACLF的肝移植等待者,发现MELD评分与ACLF分级存在交互作用,ACLF在较低MELD评分时影响更大。利用推导队列(n=9,181)建立的交互模型评分将验证队列(n=9,235)分为四分位,等待名单死亡率随四分位升高而增加(13%、18%、23%、36%),校准良好(拟合优度p=0.98,R=0.99)。
要点
- ACLF分级与MELD评分存在交互作用,低MELD评分时ACLF影响更大
- 新评分将验证队列分为四组,等待名单死亡率随评分升高而增加
- 新评分校准良好,可能优于现有评分系统
核心结论
- 在肝移植等待者中,MELD评分与ACLF分级交互预测90天等待名单死亡率,低MELD评分时ACLF分级影响更大。
- 基于交互模型开发的新评分在验证队列中显示良好校准和相关性。
研究设计与样本
- 分析UNOS数据库(2002年1月至2018年6月)中成人肝硬化伴ACLF(无肝细胞癌)的肝移植等待者。
- 共纳入18,416例等待者,平均年龄54岁,69%男性,63%白人。
- 使用改良EASL-CLIF标准定义ACLF分级1、2、3a和3b。
- 使用Fine和Gray回归模型识别变量并建立评分,推导队列n=9,181,验证队列n=9,235。
主要发现
- 90天等待名单死亡率(患者死亡或病情过重无法移植)为21.6%,ACLF分级1、2、3a、3b分别为18%、20%、25%、39%。
- 识别出MELD与ACLF分级的交互作用,ACLF在较低MELD评分时影响更大。
- 其他变量包括年龄、性别、肝病病因、等待时MELD、ACLF分级、肥胖和体能状态。
- 验证队列按评分四分位分为Q1(<10.42)、Q2(10.42-12.81)、Q3(12.82-15.50)、Q4(>15.50),等待名单死亡率分别为13%、18%、23%、36%。
- 验证队列观察与预期等待名单死亡率十分位校准良好(拟合优度p=0.98)且相关(R=0.99)。
关键数值与推荐
- ACLF分级1、2、3a、3b的90天等待名单死亡率分别为18%、20%、25%、39%。
- 新评分四分位Q1(<10.42)、Q2(10.42-12.81)、Q3(12.82-15.50)、Q4(>15.50)对应等待名单死亡率13%、18%、23%、36%。
- 验证队列校准拟合优度p=0.98,相关系数R=0.99。
临床怎么用
- 在肝移植候选者优先排序和器官分配时,可考虑同时评估MELD评分和ACLF分级。
- 新评分可能改善对肝硬化伴ACLF患者等待名单死亡风险的预测。
- 需进一步在前瞻性研究中验证该评分以支持临床决策。
局限性
- 研究为回顾性数据库分析,可能存在选择偏倚。
- 需大型前瞻性研究验证 findings。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Among candidates listed for liver transplant (LT), the model for end-stage liver disease (MELD) score may not capture acute-on-chronic liver failure (ACLF) severity. Data on the interaction between ACLF and MELD score in predicting waitlist mortality are scarce. METHODS: We analyzed the UNOS database (01/2002 to 06/2018) for LT listings in adults with cirrhosis and ACLF (without hepatocellular carcinoma). ACLF grades 1, 2, 3a, and 3b- were defined using the modified EASL-CLIF criteria. RESULTS: Of 18,416 candidates with ACLF at listing (mean age 54 years, 69% males, 63% Caucasians), 90-day waitlist mortality (patient death or being too sick for LT) was 21.6% (18%, 20%, 25%, and 39% for ACLF grades 1, 2, 3a, and 3b, respectively). Using a Fine and Gray regression model, we identified an interaction between MELD and ACLF grade, with ACLF having a higher impact at lower MELD scores. Other variables included candidate's age, sex, liver disease etiology, listing MELD, ACLF grade, obesity, and performance status. A score developed using parameter estimates from the interaction model on the derivation cohort (n = 9,181) stratified the validation cohort (n = 9,235) into quartiles: Q1 (score <10.42), Q2 (10.42-12.81), Q3 (12.82-15.50), and Q4 (>15.50). Waitlist mortality increased with each quartile from 13%, 18%, 23%, and 36%, respectively. Observed vs. expected waitlist mortality deciles in the validation cohort showed good calibration (goodness of fit p = 0.98) and correlation (R = 0.99). CONCLUSION: Among selected candidates who have ACLF at listing, MELD score and ACLF interact in predicting cumulative risk of 90-day waitlist mortality, with higher impact of ACLF grade at lower listing MELD score. Validating these findings in large prospective studies will support consideration of both MELD and ACLF when prioritizing transplant candidates and allocating liver grafts. LAY SUMMARY: In patients with cirrhosis listed for liver transplantation, the presence of multiorgan failure, a condition referred to as acute-on-chronic liver failure, is associated with high waiting list mortality rates. Current organ allocation policy disadvantages patients with this condition. This study describes and validates a new scoring method that performs better than the currently available scoring systems. Further validation of this approach may reduce the deaths of patients with cirrhosis and acute-on-chronic liver failure on the transplant waiting list.
引用
- Abdallah MA, Kuo YF, Asrani S, et al. Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality. J Hepatol. 2020. PMID: 33326814. doi:10.1016/j.jhep.2020.12.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。